⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL671744 | 0.75 | TP53 (0.54) | — | |
| SCHEMBL136867 | 0.69 | — | — | |
| SCHEMBL14865592 | 0.69 | — | — | |
| SCHEMBL3254849 | 0.67 | — | — | |
| SCHEMBL14314061 | 0.67 | — | — | |
| SCHEMBL2664411 | 0.65 | — | — | |
| SCHEMBL2459198 | 0.65 | — | — | |
| SCHEMBL138415 | 0.65 | — | — | |
| SCHEMBL3813175 | 0.65 | — | — | |
| SCHEMBL23933248 | 0.63 | MCL1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110229-A1 | Muscarinic receptor antagonists | PNC BANK, NATIONAL ASSOCIATION | 2004-06-10 | — | — | US | claimed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| EP-1457488-B1 | Intermediates for use in the preparation of urea compounds having muscarinic receptor antagonist activity | THERAVANCE INC (US) | 2009-08-12 | — | — | EP | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7238709-B2 | Therapeutic carbamates | THERAVANCE, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1235802-B1 | CARBAMATE DERIVATIVES HAVING MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE INC (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-1457488-A1 | Intermediates for use in the preparation of urea compounds having muscarinic receptor antagonist activity | Theravance, Inc. (US) | 2004-09-15 | — | — | EP | disclosed |
| EP-1235803-B1 | UREA COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE INC (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20040116706-A1 | Therapeutic ureas | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-06-17 | — | — | US | disclosed |
| US-20040110229-A1 | Muscarinic receptor antagonists | PNC BANK, NATIONAL ASSOCIATION | 2004-06-10 | — | — | US | disclosed |
| US-20040054187-A1 | Therapeutic ureas | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-03-18 | — | — | US | disclosed |
| US-6693202-B1 | MULTIBINDING LIGANDS CONTAINING SUCH AS AMINE, AMIDE, ESTER, HYDROXYL, CARBAMATE, UREA AND/OR IMINO FUNCTIONALITY | THERAVANCE, INC. | 2004-02-17 | — | — | US | disclosed |
| US-20040029919-A1 | Therapeutic carbamates | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-02-12 | — | — | US | disclosed |
| US-6635764-B2 | Urea compounds that are muscarinic receptor antagonists and agonists, administering to the mammal the urea compound to treat urinary incontinence, chronic pulmonary obstructive disease, asthma, hyper salivation, blurred vision etc. | THERAVANCE, INC. | 2003-10-21 | — | — | US | disclosed |
| CN-1407970-A | Urea compounds having muscarinic receptor antagonist activity | SHIWAN PHARMACEUTICALS INC (US) | 2003-04-02 | — | — | CN | disclosed |
| EP-1235802-A1 | CARBAMATE DERIVATIVES HAVING MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | Theravance, Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
| US-20020049195-A1 | Therapeutic ureas | THERAVANCE BIOPHARMA R&D IP, LLC | 2002-04-25 | — | — | US | disclosed |
| WO-2001042212-A1 | CARBAMATE DERIVATIVES HAVING MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE, INC. (US) | 2001-06-14 | — | — | WO | disclosed |